BALAXI

Balaxi Pharmaceuticals Share Price

₹74.73 -5.46 (-6.81%)

22 Dec, 2024 21:51

SIP TrendupStart SIP in BALAXI

Start SIP

Performance

  • Low
  • ₹73
  • High
  • ₹80
  • 52 Week Low
  • ₹73
  • 52 Week High
  • ₹151
  • Open Price₹80
  • Previous Close₹80
  • Volume52,035

Investment Returns

  • Over 1 Month -1.22%
  • Over 3 Month -32.57%
  • Over 6 Month -37.95%
  • Over 1 Year -12.05%
SIP Lightning

Smart Investing Starts Here Start SIP with Balaxi Pharmaceuticals for Steady Growth!

Invest Now

Balaxi Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 11.6
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 413
  • P/B Ratio
  • 2
  • Average True Range
  • 3.56
  • EPS
  • 5.98
  • Dividend Yield
  • 0
  • MACD Signal
  • -1.41
  • RSI
  • 30.21
  • MFI
  • 37.24

Balaxi Pharmaceuticals Financials

Balaxi Pharmaceuticals Technicals

EMA & SMA

Current Price
₹74.73
-5.46 (-6.81%)
pointer
  • stock-down_img
  • Bullish Moving Average 0
  • stock-up_img
  • Bearish Moving Average 16
  • 20 Day
  • ₹81.46
  • 50 Day
  • ₹86.40
  • 100 Day
  • ₹93.70
  • 200 Day
  • ₹99.43

Resistance and Support

76.09 Pivot Speed
  • R3 85.67
  • R2 82.93
  • R1 78.83
  • S1 71.99
  • S2 69.25
  • S3 65.15

What's your outlook on Balaxi Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Balaxi Pharmaceuticals has an operating revenue of Rs. 263.62 Cr. on a trailing 12-month basis. An annual revenue de-growth of -30% needs improvement, Pre-tax margin of 1% needs improvement, ROE of -1% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 26 which is a POOR score indicating inconsistency in earnings, a RS Rating of 5 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at D+ which indicates heavy supply, Group Rank of 53 indicates it belongs to a fair industry group of Medical-Generic Drugs and a Master Score of D is close to being the worst. Institutional holding has remained stable in the last reported quarter. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Balaxi Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-05 Quarterly Results & Others To consider other business matters. split from Rs. 10/- to Rs. 2/-.
2024-08-02 Quarterly Results
2024-05-29 Audited Results
2023-11-02 Quarterly Results
2023-08-03 Quarterly Results
Date Purpose Remarks
2024-05-30 Split Rs.0.00 split from Rs. 10/- to Rs. 2/-.

Balaxi Pharmaceuticals F&O

Balaxi Pharmaceuticals Shareholding Pattern

65.99%
16.48%
0.02%
9.24%
8.27%

About Balaxi Pharmaceuticals

  • NSE Symbol
  • BALAXI
  • BSE Symbol
  • Managing Director
  • Mr. Ashish Maheshwari
  • ISIN
  • INE618N01022

Similar Stocks to Balaxi Pharmaceuticals

Balaxi Pharmaceuticals FAQs

Balaxi Pharmaceuticals share price is ₹74 As on 22 December, 2024 | 21:37

The Market Cap of Balaxi Pharmaceuticals is ₹412.6 Cr As on 22 December, 2024 | 21:37

The P/E ratio of Balaxi Pharmaceuticals is 11.6 As on 22 December, 2024 | 21:37

The PB ratio of Balaxi Pharmaceuticals is 2 As on 22 December, 2024 | 21:37

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23